Scarica l'app Stockscreener
35.71
0.14%
0.05
Dopo l'orario di chiusura:
35.65
-0.06
-0.17%
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics: Lorundrostat’s Broad Efficacy, Favorable Safety, and Upside Indications Support Buy Rating on MLYS - TipRanks
Mineralys Therapeutics filed NDA for lorundrostat to U.S. FDA in late 2025 - marketscreener.com
Mineralys updates lorundrostat program and upcoming data milestones - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Analyzing a Potential 42.67% Upside in the Biotech Sector - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. Provides Corporate Update and Announces NDA Filing - TradingView — Track All Markets
New blood pressure drug shows promise for hard-to-treat patients - Stock Titan
Will Mineralys Therapeutics Inc. stock maintain dividend yield2026 world cup usa national team round of 32 midfield engines build up play match prediction statistical analysis - Улправда
Is Mineralys Therapeutics Getting To The Heart Of Hypertension With Lorundrostat? - RTTNews
Nasdaq Moves: Is Mineralys Therapeutics Inc stock a safe investment in uncertain marketsJuly 2025 Outlook & Real-Time Volume Spike Alerts - moha.gov.vn
Behavioral Patterns of MLYS and Institutional Flows - Stock Traders Daily
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus - ts2.tech
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.4%What's Next? - MarketBeat
Oversold Conditions For Mineralys Therapeutics (MLYS) - Nasdaq
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 38% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Simplify Asset Management Inc. Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Commit To Buy Mineralys Therapeutics At $22.50, Earn 16.1% Annualized Using Options - Nasdaq
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha
Swedbank AB Sells 84,500 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Voya Investment Management LLC Grows Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge - Yahoo Finance
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears - Yahoo Finance
If These Biotech Stocks Pull Back, I'll Be Ready to Pull the Trigger - TheStreet Pro
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
(MLYS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Analyst Upgrade: Can Mineralys Therapeutics Inc stock attract ESG capital inflowsEarnings Growth Summary & Weekly Stock Performance Updates - moha.gov.vn
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Is Mineralys Therapeutics Inc. stock near bottom after decline2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Why Mineralys Therapeutics Inc. stock is in analyst buy zone2025 Fundamental Recap & Fast Entry High Yield Stock Tips - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data - Investing.com South Africa
Can Mineralys Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Momentum & Advanced Swing Trade Entry Plans - DonanımHaber
Is Mineralys Therapeutics Inc. stock ready for breakoutIPO Watch & Weekly Return Optimization Alerts - Улправда
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsWeekly Gains Summary & High Yield Equity Trading Tips - DonanımHaber
Is Mineralys Therapeutics Inc. stock a safe investment in uncertain marketsQuarterly Profit Summary & Daily Technical Stock Forecast Reports - DonanımHaber
Analysts’ Top Healthcare Picks: Novan (NOVN), Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension - MyChesCo
Wall Street analysts think Mineralys Therapeutics, Inc. (MLYS) could surge 27.55%: Read this before placing a bet - MSN
Mineralys Therapeutics (MLYS): Reassessing Valuation After JAMA Spotlight on Lorundrostat’s Phase 3 Launch-HTN Trial - Sahm
Is Mineralys Therapeutics Inc a good long term investmentFinancial Sector Performance & Budget Friendly Trading Alerts - earlytimes.in
Did JAMA’s “Research of the Year” Nod for Launch-HTN Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Boothbay Fund Management LLC Sells 116,877 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Aug Opening: Is Mineralys Therapeutics Inc stock a contrarian buyPortfolio Performance Report & Daily Technical Stock Forecast Reports - moha.gov.vn
Biotech Shake-Up: New CEO Takes Helm at Jubilant Therapeutics - MyChesCo
Mineralys hypertension drug trial featured in JAMA’s top research of 2025 - Investing.com Canada
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):